Phase 2 MMY2002 trial of daratumumab in myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, MarĂ­a-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses the results of the phase 2 MMY2002 trial of the anti-CD38 monoclonal antibody, daratumumab, in patients with at least 3 lines of prior therapy or double refractory multiple myeloma.

Year of Production:
Running Time:
Color/Sound:

2015
02:59
Color/Sound

Comments are closed.